Axovant Sciences Ltd. | Business Contracts

Plan of Complete Liquidation and Dissolution of Sio Gene Therapies Inc (Filed With SEC on December 14, 2022)

Form of Indemnification Agreement with directors and executive officers (Filed With SEC on June 14, 2022)

Employment Agreement, dated (Filed With SEC on June 14, 2022)

Form of Pre-funded Warrant to purchase Shares of Common Stock (Filed With SEC on June 9, 2021)

Exclusive License Agreement, dated as of December 7, 2018, by and between the Registrant and the University of Massachusetts (Filed With SEC on February 7, 2019)

Amended and Restated 2015 Equity Incentive Plan (Filed With SEC on November 12, 2021)

Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Amended and Restated 2015 Equity Incentive Plan (Filed With SEC on June 9, 2021)

Description of Securities (Filed With SEC on June 9, 2021)

Sales Agreement, dated as of December 16, 2020, between Sio Gene Therapies Inc. and SVB Leerink LLC (Filed With SEC on December 18, 2020)

Form of Common Stock Certificate (Filed With SEC on November 13, 2020)

Sales Agreement, dated as of April 29, 2020, between Axovant Gene Therapies Ltd. and SVB Leerink LLC (Filed With SEC on April 29, 2020)

Form of Pre-Funded Warrant to purchase Common Shares (Filed With SEC on February 21, 2020)

Underwriting Agreement, dated February 19, 2020 (Filed With SEC on February 21, 2020)

Third Amendment to Loan and Security Agreement, dated November 27, 2019, by and among Axovant Gene Therapies Ltd., Axovant Holdings Limited, Axovant Sciences GmbH, Axovant... (Filed With SEC on December 3, 2019)

Employment Agreement, dated November 4, 2019, by and between Gavin Corcoran and Axovant Sciences, Inc (Filed With SEC on November 8, 2019)

Employment Agreement, dated November 4, 2019, by and between David Nassif and Axovant Sciences, Inc (Filed With SEC on November 8, 2019)

Employment Agreement, dated November 4, 2019, by and between Pavan Cheruvu and Axovant Sciences, Inc (Filed With SEC on November 8, 2019)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2015 Equity Incentive Plan, as amended (Filed With SEC on September 24, 2019)

Separation and General Release Agreement between Axovant Sciences, Inc. and Mathew Bazley, dated July 29, 2019 (Filed With SEC on August 9, 2019)

Separation and General Release Agreement between Axovant Sciences, Inc. and Gregory Weinhoff, M.D., dated June 28, 2019 (Filed With SEC on August 9, 2019)

Amended and Restated Services Agreement, effective as of June 10, 2019, by and among Roivant Sciences GmbH and Axovant Sciences GmbH (Filed With SEC on June 11, 2019)

Amended and Restated Services Agreement, effective as of June 10, 2019, by and among Roivant Sciences, Inc., Axovant Sciences GmbH, Axovant Sciences, Inc. and the Registrant (Filed With SEC on June 11, 2019)

Separation and General Release Agreement between Axovant Sciences, Inc. and Mark Altmeyer, dated March 16, 2019 (Filed With SEC on June 11, 2019)

Underwriting Agreement, dated March 13, 2019 (Filed With SEC on March 15, 2019)

Axovant Sciences Ltd. (24)